Q1 EPS Estimate for Ovid Therapeutics Increased by Analyst

Ovid Therapeutics Inc. (NASDAQ:OVID) – HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Ovid Therapeutics in a report issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.13) per share for the quarter, up from their prior estimate of ($0.16). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Ovid Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.15) EPS and Q4 2026 earnings at ($0.16) EPS.

Ovid Therapeutics (NASDAQ:OVID) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.19 million. Ovid Therapeutics had a negative net margin of 5,142.56% and a negative return on equity of 39.24%.

A number of other equities analysts also recently commented on the stock. Wedbush reaffirmed an “outperform” rating and set a $3.00 price objective (down from $4.00) on shares of Ovid Therapeutics in a report on Wednesday, March 12th. Oppenheimer upgraded shares of Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 price target for the company in a research note on Wednesday, January 29th. Finally, BTIG Research lowered their price objective on Ovid Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Monday. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $3.03.

Ovid Therapeutics Stock Down 6.9 %

Shares of OVID stock opened at $0.38 on Wednesday. The stock has a market cap of $26.93 million, a P/E ratio of -0.81 and a beta of 0.29. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.66 and a quick ratio of 5.66. The stock has a fifty day moving average price of $0.58 and a 200 day moving average price of $0.91. Ovid Therapeutics has a one year low of $0.37 and a one year high of $3.45.

Institutional Trading of Ovid Therapeutics

Large investors have recently added to or reduced their stakes in the company. Velan Capital Investment Management LP acquired a new position in shares of Ovid Therapeutics in the 4th quarter worth approximately $65,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Ovid Therapeutics by 50.2% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 943,416 shares of the company’s stock valued at $881,000 after purchasing an additional 315,126 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Ovid Therapeutics in the fourth quarter worth $272,000. Bank of America Corp DE grew its holdings in shares of Ovid Therapeutics by 49.7% during the fourth quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock worth $53,000 after purchasing an additional 18,841 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in shares of Ovid Therapeutics in the fourth quarter valued at $934,000. 72.24% of the stock is owned by institutional investors.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.